伊皮利穆马布,奥米克斯和头癌在2025年更新
Robert Kucharski1,2, Adam Kosiński3,4, Leszek Kalinowski1,5
1Department of Medical Laboratory Diagnostics - Fahrenheit Biobank BBMRI.pl, Medical University of Gdansk, Gdańsk, Poland.
Frontiers in immunology
|March 16, 2026
概括
免疫检查点抑制剂,如伊皮利马布和尼沃马布,在头癌症中显示出有前途. 组合疗法可能会增加疗效,但也会增加胃肠道副作用,影响治疗建议.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 微生物组研究 微生物组研究
背景情况:
- 免疫检查点抑制剂 (ICI) 对复发性和转移性头癌 (HNCs) 至关重要.
- 伊皮利穆马布 (抗CTLA-4) 和尼沃卢马布 (抗PD-1) 是单独或组合用于HNC免疫治疗的单克隆抗体.
- CTLA-4和PD-1通过不同的途径调节T细胞功能.
研究的目的:
- 评估伊皮利穆马布单一治疗与伊皮利穆马布加尼沃卢马布联合治疗在HNCs中的比较疗效.
- 研究微生物组作为HNCsICI反应的生物标志物的作用.
- 评估微生物群对与伊皮利姆巴基疗法相关的免疫相关不良事件 (irAEs) 的影响.
主要方法:
- 对Ipilimumab和Nivolumab在HNC治疗中的现有文献的综述.
- 对检查微生物组组成和ICI反应之间的关联的研究进行分析.
- 对接受组合免疫治疗的HNC患者的irAEs,特别是胃肠道副作用的数据的评估.
主要成果:
- 尽管观察到一些组合治疗的好处,但Ipilimumab与Ipilimumab加Nivolumab在HNC中的比较疗效尚不清楚.
- 微生物群对ICI的反应有影响,但对HNCs的具体数据有限.
- 一个有益的微生物群签名可能会减轻来自ipilimumab的irAEs.
- 结合伊皮利穆马布和尼沃卢马布可显著增加HNC患者的胃肠道副作用.
结论:
- 虽然联合伊皮利马布和尼沃马布可能在HNC中提供疗效益,但胃肠道副作用的发病率增加使其推变得复杂.
- 需要进一步的研究来阐明微生物组在预测ICI反应和管理HNC患者的irAEs中的作用.
- 考虑到微生物组特征的个性化治疗策略可能对于优化HNC的ICI治疗至关重要.
关键词:
头部和部癌症 头部和部癌症免疫检查点抑制剂 免疫检查点抑制剂这里是 ipilimumab 的所在地.微生物代谢物的微生物代谢物微生物组是一个微生物组.这就是尼沃卢马布 (nivolumab).更多相关视频
09:04Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
1.9K
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
2.3K
相关概念视频
Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies
1.7K
1.7K
Cancer Vaccines
1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers
1.5K
1.5K
